{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:16:19Z","timestamp":1774498579491,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clinthera.2021.06.012","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T01:59:04Z","timestamp":1627523944000},"page":"1285-1299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed\/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"C\u00f4t\u00e9-Sergent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.06.012_bib0001","doi-asserted-by":"crossref","first-page":"58638","DOI":"10.18632\/oncotarget.10716","article-title":"Gene mutations and actionable genetic lesions in mantle cell lymphoma","volume":"7","author":"Ahmed","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0002","unstructured":"Leukemia & Lymphoma Society. Mantle cell lymphoma facts. https:\/\/www.lls.org\/sites\/default\/files\/file_assets\/mantlecelllymphoma.pdf. 2021"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0003","unstructured":"National Cancer Institute. SEER cancer stat facts: non-Hodgkin lymphoma. 2020; https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed January 7, 2021."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0005","first-page":"1","article-title":"Systematic literature review of the global burden of illness of mantle cell lymphoma","author":"Monga","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0006","first-page":"755","article-title":"Hodgkin Lymphoma, Version 2.2020","volume":"18","author":"Hoppe","year":"2020","journal-title":"NCCN Clinical Practice Guidelines in Oncology"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0007","unstructured":"American Cancer Society (ACS). Treating B-Cell Non-Hodgkin Lymphoma [ACS website]. 2020. Available at: https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/treating\/b-cell-lymphoma.html. Accessed January 12, 2021."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0008","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines: B-Cell Lymphomas version 4.2020 [NCCN website]. 2020. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed January 7, 2021."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0009","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database","volume":"119","author":"LaCasce","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0010","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0011","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11899-016-0324-3","article-title":"Which patients with mantle cell lymphoma do not need aggressive therapy","volume":"11","author":"Ruan","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0012","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2017.167627","article-title":"European Mantle Cell Lymphoma Network. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?","volume":"102","author":"Ferrero","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0013","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14122.1","article-title":"Current overview and treatment of mantle cell lymphoma","volume":"7","author":"Schieber","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0014","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/10428194.2017.1403602","article-title":"Treatment for patients with relapsed\/refractory mantle cell lymphoma: European-based recommendations","volume":"59","author":"Dreyling","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0015","unstructured":"Velcade (bortezomib) [prescribing information]. 2019. Available at: https:\/\/www.velcade.com\/files\/pdfs\/velcade_prescribing_information.pdf. Accessed October 28, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0016","unstructured":"Revlimid (lenalidomide) [prescribing information]. 2013. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021880s034lbl.pdf. Accessed October 28, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0017","unstructured":"Imbruvica (ibrutinib) [prescribing information]. 2019. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/205552s029,210563s004lbl.pdf. Accessed February 15, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0018","unstructured":"Calquence (acalabrutinib) [prescribing information]. 2017. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf. Accessed October 28, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10020","key":"10.1016\/j.clinthera.2021.06.012_bib0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.06.012_bib0021","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2019-124691","article-title":"Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up","volume":"134","author":"Rule","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0023","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1002\/cam4.2559","article-title":"Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0024","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/10428194.2018.1509320","article-title":"Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States","volume":"60","author":"Goyal","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.06.012_bib0025","first-page":"3442","article-title":"Adverse events, resource use, and economic burden in patients with mantle cell lymphoma in the United States","volume":"130","author":"Karve","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0026","unstructured":"Centers for Medicare & Medicaid Services (CMS). Oncology Care Model Fact Sheet [CMS website]. 2016. Available at: https:\/\/www.cms.gov\/Newsroom\/mediareleasedatabase\/fact-sheets\/2016-fact-sheets-items\/2016-06-29.html. Accessed September 15, 2018."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0027","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","article-title":"Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States","volume":"37","author":"Henk","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0028","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.clinthera.2016.07.004","article-title":"Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: results of an oncology EMR analysis","volume":"38","author":"Malangone-Monaco","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0029","unstructured":"Rituxan (rituximab) [prescribing information]. 2020. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103705s5454lbl.pdf. Accessed February 13, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0030","unstructured":"Gazyva (obinutuzumab) [prescribing information]. 2020. Available at: https:\/\/www.gene.com\/download\/pdf\/gazyva_prescribing.pdf. Accessed February 13, 2020."},{"key":"10.1016\/j.clinthera.2021.06.012_bib0031","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0032","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Communications in Statistics - Simulation and Computation"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0033","series-title":"Statistical Power Analysis for the Behavioral Sciences","first-page":"20","author":"Cohen","year":"1988"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2021.06.012_bib0034","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.jval.2019.04.268","article-title":"PCN144 Ibrutinib treatment is associated with lower healthcare resource utilization and total cost reduction compared to chemoimmunotherapy in patients with mantle cell lymphoma","volume":"22","author":"Iyengar","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2021.06.012_bib0035","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s12325-015-0270-9","article-title":"Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer","volume":"32","author":"Hess","year":"2015","journal-title":"Adv Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:00Z","timestamp":1758963300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0149291821002435"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed\/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}